{"groups":[{"description":"Participants received rituximab as an intravenous (IV) infusion of 375 milligrams per meter squared (mg/m\\^2) once a week on Days 1, 8, 15 and 22 during the Remission Induction Phase (Day 1 (baseline) to Month 6) and were followed for a minimum of 18 months (maximum 4.5yrs) during the Follow-up Phase until the Common-closeout (CCO))","id":"FG000","title":"Rituximab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Transferred Back to Local Hospital"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Physician and Family Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Transferred to Adult Services"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"25"}],"comment":"Remission Induction Phase (Day 1 to Month 6)","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"25"}],"comment":"Remission Induction Phase (Day 1 to Month 6)","type":"Completed"},{"achievements":[{"comment":"Completed required follow-up","groupId":"FG000","numSubjects":"24"}],"comment":"(Month 6 to Month 18)","type":"Follow-up Phase"},{"achievements":[{"comment":"Completed to CCO. 6 participants entered Extended Safety Follow-up, 10 participants completed Study.","groupId":"FG000","numSubjects":"16"}],"comment":"Completed until CCO (Month 18 up to 4.5 years)","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"9"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"The screening visit occurred up to 28 days prior to the Day 1 baseline visit. Following successful screening, eligible participants entered the 6 month Remission Induction Phase of the study.","recruitmentDetails":"A total of 25 participants were enrolled in the study over a 3.5 year period from 11 sites across the United Kingdom, Italy, Serbia, Turkey, Canada and the United States."}